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Summary Systemically administered radiolabelled anti-tumour antibody is ineffective in treating the majority
of patients with liver metastasis from colorectal carcinoma. We have assessed whether agents which increase
capillary permeability can increase tumour uptake of antibody isotope conjugate. We developed a xenograft
model of colorectal carcinoma using an antibody directed against carcinoembryonic antigen (CEA). Tumours
were grown subcutaneously in the hind limbs of athymic rats to derive their circulation from the femoral
artery. Cannulae were placed in the common iliac artery and iliolumbar vein. Antibody was delivered
systemically, regionally and regionally with histamine, leukotriene C4 and interleukin-2.
Regionally administered anti-CEA antibody resulted in a significantly greater (P = 0.004) tumour to normal
tissue ratio (1.66, s.d. = 0.68) compared to systemically administered antibody (1.25, s.d. = 0.73). The addition
of vasoactive drugs produced an approximately 3-fold increase with an increase to a mean tumour:liver ratio
of 3.24 (s.d. = 1.39) for histamine (P <0.001 compared to systemic delivery), 3.21 (s.d. = 1.13, P <0.001) for
leukotriene C4 and 3.80 (s.d. = 1.53, P <0.001) for interleukin-2.
The addition of histamine significantly (P = 0.004) increased the mean tumour to liver ratio (1.73,
s.d. = 0.44) of non-specific antibody uptake compared with either systemic (1.12, s.d. = 0.24) or regional
delivery (1.25, s.d. = 0.54) of non-specific antibody alone.
Increasing tumour capillary permeability can produce a significant clinically useful increase in tumour
uptake of antibody-isotope conjugate.
Treatment of disseminated colorectal carcinoma using
systemically administered anti-tumour antibody labelled with
a therapeutic dose of iodine 131 has produced poor responses
(Begent et al., 1989) because of low tumour antibody uptake.
The uptake of antibody from the circulation depends on
intravascular dose, tumour blood flow (Sands et al., 1986)
and capillary permeability (Sands et al., 1988). In the case of
antibody macromolecules (IgG, molecular weight 150,000
daltons) capillary permeability is an important limitation to
tissue uptake (Halpern et al., 1986; Sands et al., 1985).
We assessed the value of increasing capillary permeability
by using agents known to increase capillary permeability in
normal tissues. The agents selected were the vasodilator
autocoid histamine (Douglas, 1980), the vasoconstrictor
eicosanoid leukotriene C4 (Frolich & Yoshizawa, 1987; Goetz
et al., 1987; Badr, 1984) and the biological response modifier
interleukin-2 (Rosenstein et al., 1986) which has minimal
influence on vasomotor tone. Since these agents all have a
short half life, they were administered regionally to enhance
local effect and reduce systemic toxicity.
To assess whether these agents could increase uptake of
antibody, we first developed a xenograft model which allows
cannulation of tumour circulation and regional infusion of
antibody to a human colorectal carcinoma expressing car-
cinoembryonic antigen (CEA).
Methods
Two antibody conjugates were prepared: specific anti-CEA
antibody (A5B7) labelled with iodine 131 and non-specific
antibody (anti-HCG antibody, SB10) labelled with iodine
125. Both were labelled using the chloramine T method
(Greenwood et al., 1963).
Genetically immunocompromised rats (150-200 g) were
maintained in a negative pressure isolator (Isotec, Bicester)
and fed on sterile water and irradiated feed ad libitum. One
million cells from a human colon cancer cell line (LS174T) in
0.1 ml of complete medium (Gibco, Uxbridge) were injected
subcutaneously into the mid-thigh of the hind limb. Once
solid tumour had grown the tumour line was serially pas-
saged by implanting diced fragments of these tumours (mean
weight 15mg) into the subcutaneous fat of the hind limb.
Arteriography confirmed that the tumours grew to derive
their blood supply from the femoral artery (Figure 1).
Figure 1 Arteriogram performed through the femoral artery
cannula. The tumour (T) has filled with contrast supplied directly
via the femoral artery cannula (arrow). The bladder has been
filled with contrast excreted via the kidneys.
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When 300-600 mg tumours, determined by calliper
measurements and volume approximation (Staab & Anderer,
1982) had grown the animal was anaesthetised the two can-
nulae (Portex 0.4mm internal diameter, Arterial Medical
Supplies, London) were inserted via a laparotomy incision.
The first ('venous' or 'systemic') cannula was inserted into
the right iliolumbar vein so that its tip lay at the junction of
the iliolumbar vein and the inferior vena cava to gain access
to the systemic circulation. The second ('arterial' or
'6regional') cannula was passed retrogradely into the right
common iliac artery so that its tip lay at the aortic bifurca-
tion to gain -access to the arterial supply to the contralateral
tumour-bearing limb.
Antibody was then administered. In 24 animals the
infusion of anti-carcinoembryonic antigen antibody (A5B7)
labelled with iodine 131 was delivered into the systemic
cannula with an infusion of saline delivered regionally. In 24
animals the situation was reversed and the conjugate
delivered regionally with a control infusion of saline given
systemically. In 30 animals the conjugate was mixed with
histamine (Sigmna, 5 mgkg-', n = 12), leukotriene C4 (Sigma,
25 mcg/animal, n = 8) or interleukin-2 (100,000 units/animal,
n = 10) and then delivered regionally. The agents were
prepared in degassed phosphate buffer at pH 7.4.
After a 1 h infusion, the abdomen was re-opened and the
cannulae removed, carefully preserving flow to the tumour
bearing limb and the animal was then recovered. After 48 h
the animnal was again anaesthetised and the liver and tumour
excised and weighed. Liver and tumour radioactivity was
measured in a well counter to determine a tumour to liver
gamma counts ratio.
Results
The tumour to liver ratio of counts obtained in each group is
shown in Figure 2.
Tumour to liver ratio ofnon-specific antibody
Systemic administration of antibody via the inferior vena
cava achieved a mean tumour to liver ratio of 1.12
(s.d. = 0.24). Regional delivery of antibody resulted in a
tumour to liver ratio of 1.25 (s.d. = 0.54) which was not
significantly greater (unpaired t-test) than after systemic
delivery. The addition of histamine to the regionally delivered
antibody produced a mean tumour to liver ratio of 1.73
(s.d. = 0.44) which was significantly (P =0.004) greater than
after systemic delivery.
Tumour to liver ratio ofspecifilc antibody
Systemic administration of antibody via the inferior vena
cava achieved a mean tumour to liver ratio of 1.25
(s.d. = 0.73). Regional delivery of antibody resulted in a
mean tumour to liver ratio of 1.66 (s.d. = 0.68) which was
significantly (P = 0.048) greater (unpaired t-test) than after
systemic delivery. The addition of histamine to the regionally
delivered antibody produced a mean tumour to liver ratio of
3.24 (s.d. = 1.39) which was significantly (P <0.001) greater
than after systemic delivery. Similarly, the mean tumour to
liver ratio was 3.21 (s.d. = 1.13, P <0.001) after administra-
tion of leukotriene C4 and 3.80 (s.d. = 1.53, P <0.001) for
interleukin-2.
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Figure 2 There was a significant increase in tumour:liver counts
if a capillary permeability agent was administered with speci'fic or
non-specific labelled antibody compared with labelled antibody
alone.
increase compared to systemic administration. Regional
delivery is of greatest advantage where the agent admini-
stered has a high first pass extraction from the tumour
vascular bed. Since the first pass extraction of antibodies is
small (Halpern et al., 1986), regional delivery would not be
expected to provide a great increase in antibody uptake into
tumour.
Regional delivery was used primarily as a means of deliver-
ing short-acting vasoactive agents to the tumour circulation.
We found that agents which increase capillary permeability
in normal capillaries increased the uptake of antibody. Our
study does not prove that the mechanisms of this increase
was change in capillary permeability. However, each of the
agents used has a different effect on microcirculation resist-
ance and the effect observed was of a similar order ofmagni-
tude for all three agents. As increase in capillary permeability
was the common factor, this is a likely explanation for the
observed increase in antibody uptake.
This suggests that these agents are capable not only of
influencing capillary permeability in normal tissues but also
in the tumour circulation where capillaries are more rudimnen-
tary and varied in structure (Tannock & Steel, 1969; Vaupel,
1975). The finding that a similar effect was observed for
non-specific antibody is compatible with enhancement of
capillary permeability. However the smaller increase com-
pared with specific antibody suggests that antigen-antibody
binding contributed to the tumour labelled-antibody concen-
tration.
The use of agents which increase capillary permeability in
normal tissues can achieve an approximate 3-fold increase in
specific antibody uptake. If radioimmunotherapy is to be
effective, a 10-fold increase in antibody uptake relative to
normal tissue may be required (Dykes et al., 1987) although
more modest increases may be of value in some patients
(Begent et al., 1989). The increase seen in this study, using
regional delivery of agents which increase capillary
permeability in normal tissues, is of sufficient magnitude to
offer a prospect of therapeutic benefit if these findings were
to be reproduced in man.
Discussion
Regional delivery of labelled antibody into the arterial supply
to the tumour-bearing limb produced only a small (33%)
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